Last reviewed · How we verify
Xarlin (Levocetirizine)
Levocetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on mast cells and basophils, reducing allergic symptoms.
Levocetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on mast cells and basophils, reducing allergic symptoms. Used for Allergic rhinitis, Chronic urticaria, Allergic conjunctivitis.
At a glance
| Generic name | Xarlin (Levocetirizine) |
|---|---|
| Also known as | Cosalin (Petasites hybridus CO2 extract), Xyarin (levocetirizine) |
| Sponsor | HK inno.N Corporation |
| Drug class | H1-receptor antagonist (second-generation antihistamine) |
| Target | H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
Levocetirizine is the active R-enantiomer of cetirizine, a second-generation antihistamine. It crosses the blood-brain barrier minimally, reducing sedation compared to first-generation antihistamines. By competitively blocking H1 receptors, it prevents histamine-mediated allergic responses including itching, urticaria, and rhinitis.
Approved indications
- Allergic rhinitis
- Chronic urticaria
- Allergic conjunctivitis
Common side effects
- Somnolence
- Headache
- Fatigue
- Dry mouth
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xarlin (Levocetirizine) CI brief — competitive landscape report
- Xarlin (Levocetirizine) updates RSS · CI watch RSS
- HK inno.N Corporation portfolio CI